In the world of brain-computer interfaces (BCIs), China has made a significant stride, gaining a head start over the likes of Neuralink. But this isn't a straightforward race to the finish line. The key difference lies in the placement of the sensors: China's NEO implant rests on the brain's protective membrane, while Neuralink's chip pierces the cortex itself. This subtle distinction has major implications, from risk profiles to regulatory clearances. While Neuralink's approach aims for high-resolution neural interfaces, China's NEO prioritizes accessibility and societal deployment. This divergence in priorities is more than just a regulatory timing gap; it reflects different definitions of what BCIs are for. The US and China are on different paths, each with its own tradeoffs and priorities. This isn't a zero-sum game, but rather a multifaceted exploration of what BCIs can do. As China's BCI industry moves forward, the focus on large-scale manufacturing and clinical deployment is a significant step. However, the immediate question is how this translates into actual patient access at scale. The approval is just the beginning, and the real test lies in the practical implementation and accessibility of these devices. The story of BCIs is far from over, and the race is not just about who gets there first, but also about how they get there and what they can achieve along the way.
